Show simple item record

dc.contributor.authorShah, Nina
dc.contributor.authorAiello, Jack
dc.contributor.authorAvigan, David E
dc.contributor.authorBerdeja, Jesus G
dc.contributor.authorBorrello, Ivan M
dc.contributor.authorChari, Ajai
dc.contributor.authorCohen, Adam D
dc.contributor.authorGanapathi, Karthik
dc.contributor.authorGray, Lissa
dc.contributor.authorGreen, Damian
dc.contributor.authorKrishnan, Amrita
dc.contributor.authorLin, Yi
dc.contributor.authorManasanch, Elisabet
dc.contributor.authorMunshi, Nikhil C
dc.contributor.authorNooka, Ajay K
dc.contributor.authorRapoport, Aaron P
dc.contributor.authorSmith, Eric L
dc.contributor.authorVij, Ravi
dc.contributor.authorDhodapkar, Madhav
dc.date.accessioned2020-07-27T13:38:16Z
dc.date.available2020-07-27T13:38:16Z
dc.date.issued2020-07-12
dc.identifier.urihttp://hdl.handle.net/10713/13407
dc.description.abstractOutcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.en_US
dc.description.urihttps://doi.org/10.1136/jitc-2020-000734en_US
dc.language.isoen_USen_US
dc.publisherBMJen_US
dc.relation.ispartofJournal for ImmunoTherapy of Canceren_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectImmunologyen_US
dc.subjectImmunology and Allergyen_US
dc.subjectMolecular Medicineen_US
dc.subjectCancer Researchen_US
dc.subjectOncologyen_US
dc.subjectPharmacologyen_US
dc.titleThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/jitc-2020-000734
dc.source.journaltitleJournal for ImmunoTherapy of Cancer
dc.source.volume8
dc.source.issue2
dc.source.beginpagee000734


This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/